This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Antimicrobial Sales and Use (ASU) Platform: Release notes
EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9...
HMPC meeting report on European Union herbal monographs, guidelines and other ac...
Human medicines European public assessment report (EPAR): Duloxetine Viatris (pr...
Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...
Human medicines European public assessment report (EPAR): Pemetrexed Fresenius K...
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,av...
Human medicines European public assessment report (EPAR): Pemetrexed Accord, pem...
Agenda - European medicines agencies network strategy (EMANS) to 2028 - webinar
Nilotinib product-specific bioequivalence guidance
Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg pro...
Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Myalepta, metreleptin,...
Herbal medicinal product: Boldi foliumArray, C: ongoing call for scientific data
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,...
Human medicines European public assessment report (EPAR): Karvezide, irbesartan,...
Human medicines European public assessment report (EPAR): Repaglinide Teva, repa...
Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for S...
Human medicines European public assessment report (EPAR): Aprovel, irbesartan, D...
Executive Steering Group on Shortages and Safety of Medicinal Products
Human medicines European public assessment report (EPAR): Ultibro Breezhaler, in...